In patients with an aggressive form of mastocytosis, characterized by increasing mast cell accumulation in different organs, leading to dysfunction, the multikinase inhibitors midostaurin or avapritinib (1) can be used to help control end-organ damage, cytopenias, and mast cell accumulation in bone marrow (2).